NCT05781048 2026-03-10
A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Active not recruiting
Clinical Trials
270 trialsNCT06596473 2026-03-05
A Study of BG-C477 in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07387068 2026-03-04
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
Genmab
Phase 1 Recruiting
NCT07446816 2026-03-03
A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 1 Recruiting
NCT06715124 2026-03-02
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
Quanta Therapeutics
Phase 1 Active not recruiting
NCT05109975 2026-02-27
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors
Debiopharm International SA
Phase 1 Active not recruiting
NCT05914376 2026-02-27
Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors
Hangzhou Converd Co., Ltd.
Phase 1 Active not recruiting
NCT05800964 2026-02-17
Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
Amgen
Phase 1 Completed
NCT06779851 2026-02-13
SUMMIT-1
Bright Peak Therapeutics Inc
Phase 1 Active not recruiting
NCT05067283 2026-02-12
KANDLELIT-001
Merck Sharp & Dohme LLC
Phase 1 Recruiting
NCT05620017 2026-02-09
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection
Bio-Thera Solutions
Phase 1 Recruiting
NCT06331559 2026-02-09
Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Terminated
NCT06480552 2026-02-05
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Recruiting
NCT07215637 2026-02-02
Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors
Chong Kun Dang Pharmaceutical
Phase 1 Recruiting
NCT07377591 2026-01-30
A Study of HDM2006 in Patients With Advanced Solid Tumor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06792552 2026-01-29
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NextCure, Inc.
Phase 1 Recruiting
NCT07042100 2026-01-22
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
Sun Pharma Advanced Research Company Limited
Phase 1 Recruiting
NCT05868915 2026-01-21
HV-101 for Patients With Advanced Solid Tumors
Hervor Therapeutics
Phase 1 Terminated
NCT06770569 2026-01-21
Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors
Shandong Suncadia Medicine Co., Ltd.
Phase 1 Recruiting
NCT07356453 2026-01-21
A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.
FoRx Therapeutics AG
Phase 1 Recruiting
NCT06927570 2026-01-16
A Study of HS-20122 in Patients With Advanced Solid Tumors
Hansoh BioMedical R&D Company
Phase 1 Recruiting
NCT07186452 2026-01-16
Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors
Hansoh BioMedical R&D Company
Phase 1 Recruiting
NCT07231458 2026-01-16
A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies
Abalos Therapeutics GmbH
Phase 1 Recruiting
NCT06990464 2026-01-08
A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor Patients
Shanghai Institute Of Biological Products
Phase 1 Recruiting
NCT05864573 2026-01-05
Study of ZGGS15 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1 Completed
NCT07252414 2026-01-05
GenSci143 in Participants With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06384352 2026-01-02
A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1 Recruiting
NCT07310134 2026-01-02
Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Advanced Solid Tumors
Nanjing Zenshine Pharmaceuticals
Phase 1 Recruiting
NCT06882135 2025-12-29
HW071021 Monotherapy in Patients With Advanced Solid Tumors
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Phase 1 Recruiting
NCT07230977 2025-12-24
GenSci139 in Patients With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT07251166 2025-12-24
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of GenSci140 in Participants With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT05240898 2025-12-18
A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT05287399 2025-12-18
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors
Ascletis Pharma Inc
Phase 1 Completed
NCT07266285 2025-12-17
BTM-3566 in Advanced Solid Tumors
Bantam Pharmaceuticals
Phase 1 Recruiting
NCT07275853 2025-12-10
Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors
TCRx Therapeutics Co.Ltd
Phase 1 Not yet recruiting
NCT05105971 2025-12-08
Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China
Bio-Thera Solutions
Phase 1 Completed
NCT06736327 2025-12-08
A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1 Recruiting
NCT03968653 2025-12-05
Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors
Debiopharm International SA
Phase 1 Terminated
NCT05387928 2025-12-05
A Study of KL340399 in Patients With Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1 Completed
NCT05549804 2025-12-05
A Study of Intratumoral KL340399 in Patients With Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1 Completed
NCT06428331 2025-12-05
A Study of SKB518 in Patients With Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1 Recruiting
NCT06826040 2025-12-05
SKB445 for Injection in Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1 Recruiting
NCT07208136 2025-12-01
A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors
Jemincare
Phase 1 Recruiting
NCT06238401 2025-11-24
An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors
Hangzhou Adcoris Biopharmacy Co., Ltd
Phase 1 Recruiting
NCT05367635 2025-11-17
A Study of SKB315 in Patients With Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1 Recruiting
NCT06618651 2025-11-17
A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1 Recruiting
NCT07229898 2025-11-17
A Phase â… Clinical Study of GEN-725 Tablets in Patients With Advanced Solid Tumors
Henan Genuine Biotech Co., Ltd.
Phase 1 Recruiting
NCT04185883 2025-10-22
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
Phase 1 Active not recruiting
NCT03522142 2025-10-09
A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
Incyte Corporation
Phase 1 Terminated
NCT04058756 2025-10-07
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
Novartis
Phase 1 Active not recruiting